This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Why Dentsply International (XRAY) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Dentsply International (XRAY) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Here's Why Dentsply International (XRAY) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Dentsply International (XRAY) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Dentsply International (XRAY) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dentsply (XRAY) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DENTSPLY SIRONA (XRAY) Q4 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.
Dentsply International (XRAY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 2.33% and 4.50%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 5.19% and 1.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Stay Ahead of the Game With Dentsply (XRAY) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Dentsply (XRAY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
What's in Store for West Pharmaceutical (WST) in Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Insulet (PODD) is expected to have benefited from the ongoing rollout of Omnipod 5 in several international markets in the fourth quarter.
Ecolab (ECL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to be driven by its Food & Beverage, Water business along with the Institutional segment.
Will Dentsply (XRAY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
McKesson (MCK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
DexCom (DXCM) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2023 results are likely to reflect rising volumes across all channels.
GE HealthCare (GEHC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance, driven by consistent NPIs and growing customer demand.
Cardinal Health (CAH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 16.67% and 1.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health (CAH) in Q2 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) second-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.
Cencora (COR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Cencora's (COR) first-quarter fiscal 2024 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.